67693-25-8

Upstream product

• 6336-16-9 benzyl 3,4-O-isopropylidene-β-D-arabinopyranoside 
• 100-39-0 benzyl bromide 
• 129840-46-6 1,2-di-O-benzyl-3,4-O-isopropylidene-β-D-arabinopyranoside 

Downstream Products

• 129840-47-7 (2R,3S,4R,5R)-5-Azido-2,3,4-tris-benzyloxy-tetrahydro-pyran 
• 129895-03-0 (3S,4R,5S,6R)-4,5,6-Tris(benzyloxy)tetrahydro-2H-pyran-3-ol 
• 67693-27-0 (3R,4R,5S,6R)-4,5,6-Tris(benzyloxy)tetrahydro-2H-pyran-3-ol 
• 67693-26-9 (2R,3S,4R,5R)-2,3,5-Tris-benzyloxy-tetrahydro-pyran-4-ol 

Relevant academic research and scientific papers

The search for a potentially prebiotic synthesis of nucleotides via arabinose-3-phosphate and its cyanamide derivative

For the RNA world hypothesis to be accepted, the constitutional self-assembly of RNA will have to be demonstrated. Conceptually, the simplest route to RNA involves nucleotide polymerisation. Activated pyrimidine nucleotides can be derived from arabinose-3

NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES

A method for preparing isofagomine, its derivatives, intermediates and salts thereof using novel processes to make isofagomine from D-(-)-arabinose and L-(-)-xylose.

Tartrate sale of isofagomine and methods of use

A novel tartaric acid salt of Isafagomine (Isofagomine tartrate) that can be used for the treatment of Gaucher disease is provided. The invention also provides a crystalline form of isofagomine tartrate, method for preparing the salt, a pharmaceutical composition containing the salt, and a method of treating Gaucher disease.